CXCL10 詳細
Molecule Name
C-X-C motif chemokine ligand 10
分子の別称
C-X-C motif chemokine 10,10 kDa interferon gamma-induced protein,Gamma-IP10,IP-10,Small-inducible cytokine B10,CXCL10(1-73),CXCL10,INP10, SCYB10
Drug Development Progress
治験薬の数2
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
Protein 10 From Interferon (Gamma)-Induced Cell Line，CXCL10，INP10，SCYB10，C-X-C motif chemokine 10，10 kDa interferon gamma-induced protein，IP-10，C-X-C Motif Chemokine Ligand 10，Small Inducible Cytokine Subfamily B (Cys-X-Cys)， Member 10，Chemokine (C-X-C Motif) Ligand 10，Small-Inducible Cytokine B10，Chemokine CXCL10，Interferon-Inducible Cytokine IP-10，Gamma IP10，Gamma-IP10，GIP-10，IFI10，Crg-2，Mob-1，C7
バックグランド
C-X-C Motif Chemokine Ligand 10 (CXCL10) is a pro-inflammatory chemokine secreted by a wide spectrum of cells. It is involved in multiple mechanisms and reported to have pleiotropic effects, including immune cell migration and attraction to inflammation sites, angiogenesis, and cancer cell growth. CXCL10 is produced by pancreatic islet cells upon inflammatory stress and is specifically recognized by C-X-C Motif Chemokine Receptor 3 (CXCR3) which is expressed by activated T-lymphocytes and other immune cells.
CXCL10 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| JT-02 (JYANT Technologies) | JT-02 | Phase 2 Clinical | Jyant Technologies | Inflammatory Bowel Diseases | 詳細 |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | 詳細 |